US biotech company Graviton Bioscience announced on Thursday a strategic investment by French pharmaceutical giant Sanofi.

Under the terms of the agreement, Sanofi will receive a right of first negotiation to license several of the New York-based company's compounds in immunological and metabolic indications.

Graviton specializes in the 'Rock2' kinases of the AGC family, and in the role played by Rho family GTPases in numerous autoimmune, inflammatory and neurological diseases.

According to Paul Hudson, Sanofi's CEO, Graviton's scientific expertise could drive a new wave of innovation and significantly improve the landscape of therapeutic possibilities.

Copyright (c) 2024 CercleFinance.com. All rights reserved.